Gapping up
In reaction to strong earnings/guidance: IDTI +9.5%, ( to acquire ZMDI for $310 mln; transaction will add $20 mln of quarterly revenues and be accretive to earnings in first full quarter following close ), BABA +8.5%, ASC +6.9%, EW +6%, SAVE +5.4%, AGEN +5.2%, CNC +5.1%, COH +4.9%, PCRX +4.8%, ROSG +4.4%, MGLN +4.2%, AGII +3.7%, BMY +3.6%, PAH+3.4%, ONE +3.2%, PFE +2.8%, UTHR +2.8%, YNDX +1.8%, MDSO +1.7%, CIGI +1.4%, MRK +1.2%, TXT +1.1%, BP +1.1%, .
M&A news: PRSN +166.6% (to be acquired by Galil Medical for $1.00/share, or ~$10.6 mln), TRIV +55% (TriVascular Technologies to be acquired by Endologix (ELGX) for $9.10/share, or ~$211 mln), RIVR +29.6% (German American Bancorp to acquire River Valley Bancorp, whereby shareholders will receive 0.770 shares of GABC stock and $9.90/share in cash per RIVR share)
Select China related stocks trading higher after BABA earnings: WBAI +5.6%, JD +4.7%, DANG +3.5%, JMEI +3%, BIDU +1.9%
Other news: UQM +24.6% (supply agreement with ITL Efficiency Corporation in China news), ASTI +18.2% (announced it is working closely with Bye Aerospace, to develop an aircraft to fill the gap between mapping and surveillance of Mars from orbital satellites and ground-based rovers), CYTK +13.9% (Amgen and Cytokinetics Incorporated (CYTK) announce top-line results from COSMIC-HF), SBBP +9.2% (RA Capital Management discloses 12.7% passive stake in 13G filing), SHPG +5.6% (announces positive topline results from OPUS-3, a phase 3 efficacy and safety study of lifitegrast versus placebo, trial met primary endpoint), AGEN +5.2% (announces that GSK's second pivotal Phase III efficacy study of its shingles vaccine candidate containing Agenus' QS-21 Stimulon-adjuvant ), YHOO +5.1% (in symp with BABA), PBMD +3.3% (announces first regulatory approval facilitating commencement of a Phase IIb clinical study of IMP321; trial initiation is expected before the end of 2015), LOOK +2.8% (shareholders approved reverse split and spin-off of co's assets and liabilities into LookSmart Group, Inc.), RMBS+2.5% (approves accelerated share repurchase program of ~$100 mln in common stock), MNGA +2.5% (reports that its cutting fuel has been selected for five major demolition projects in Florida), TWTR +1.7% (IBM announces collaboration with Twitter and The Weather Channel), TASR +1.6% (Reuters reporting that Baltimore's Police Department has begun testing body cameras with its officers) AA +1.3% (positive commentary on Mad Money)
Analyst comments: VMW +1.8% (upgraded to Buy from Hold at Drexel Hamilton)
In reaction to strong earnings/guidance: IDTI +9.5%, ( to acquire ZMDI for $310 mln; transaction will add $20 mln of quarterly revenues and be accretive to earnings in first full quarter following close ), BABA +8.5%, ASC +6.9%, EW +6%, SAVE +5.4%, AGEN +5.2%, CNC +5.1%, COH +4.9%, PCRX +4.8%, ROSG +4.4%, MGLN +4.2%, AGII +3.7%, BMY +3.6%, PAH+3.4%, ONE +3.2%, PFE +2.8%, UTHR +2.8%, YNDX +1.8%, MDSO +1.7%, CIGI +1.4%, MRK +1.2%, TXT +1.1%, BP +1.1%, .
M&A news: PRSN +166.6% (to be acquired by Galil Medical for $1.00/share, or ~$10.6 mln), TRIV +55% (TriVascular Technologies to be acquired by Endologix (ELGX) for $9.10/share, or ~$211 mln), RIVR +29.6% (German American Bancorp to acquire River Valley Bancorp, whereby shareholders will receive 0.770 shares of GABC stock and $9.90/share in cash per RIVR share)
Select China related stocks trading higher after BABA earnings: WBAI +5.6%, JD +4.7%, DANG +3.5%, JMEI +3%, BIDU +1.9%
Other news: UQM +24.6% (supply agreement with ITL Efficiency Corporation in China news), ASTI +18.2% (announced it is working closely with Bye Aerospace, to develop an aircraft to fill the gap between mapping and surveillance of Mars from orbital satellites and ground-based rovers), CYTK +13.9% (Amgen and Cytokinetics Incorporated (CYTK) announce top-line results from COSMIC-HF), SBBP +9.2% (RA Capital Management discloses 12.7% passive stake in 13G filing), SHPG +5.6% (announces positive topline results from OPUS-3, a phase 3 efficacy and safety study of lifitegrast versus placebo, trial met primary endpoint), AGEN +5.2% (announces that GSK's second pivotal Phase III efficacy study of its shingles vaccine candidate containing Agenus' QS-21 Stimulon-adjuvant ), YHOO +5.1% (in symp with BABA), PBMD +3.3% (announces first regulatory approval facilitating commencement of a Phase IIb clinical study of IMP321; trial initiation is expected before the end of 2015), LOOK +2.8% (shareholders approved reverse split and spin-off of co's assets and liabilities into LookSmart Group, Inc.), RMBS+2.5% (approves accelerated share repurchase program of ~$100 mln in common stock), MNGA +2.5% (reports that its cutting fuel has been selected for five major demolition projects in Florida), TWTR +1.7% (IBM announces collaboration with Twitter and The Weather Channel), TASR +1.6% (Reuters reporting that Baltimore's Police Department has begun testing body cameras with its officers) AA +1.3% (positive commentary on Mad Money)
Analyst comments: VMW +1.8% (upgraded to Buy from Hold at Drexel Hamilton)